Works matching IS 15391604 AND DT 2020 AND VI 19 AND IP 6
Results: 17
A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 975, doi. 10.1002/pst.2049
- By:
- Publication type:
- Article
Evaluating the time‐dependent predictive accuracy for event‐to‐time outcome with a cure fraction.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 955, doi. 10.1002/pst.2048
- By:
- Publication type:
- Article
Score and deviance residuals based on the full likelihood approach in survival analysis.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 940, doi. 10.1002/pst.2047
- By:
- Publication type:
- Article
Comparing Bayesian early stopping boundaries for phase II clinical trials.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 928, doi. 10.1002/pst.2046
- By:
- Publication type:
- Article
Assurance for clinical trial design with normally distributed outcomes: Eliciting uncertainty about variances.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 827, doi. 10.1002/pst.2040
- By:
- Publication type:
- Article
Regional consistency and sample size considerations in a multiregional equivalence trial.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 897, doi. 10.1002/pst.2044
- By:
- Publication type:
- Article
Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 882, doi. 10.1002/pst.2043
- By:
- Publication type:
- Article
Optimal decision‐making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 861, doi. 10.1002/pst.2042
- By:
- Publication type:
- Article
Imputation of missing covariate in randomized controlled trials with a continuous outcome: Scoping review and new results.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 840, doi. 10.1002/pst.2041
- By:
- Publication type:
- Article
MMRM vs joint modeling of longitudinal responses and time to study drug discontinuation in clinical trials using a "de jure" estimand.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 909, doi. 10.1002/pst.2045
- By:
- Publication type:
- Article
A Bayesian approach in design and analysis of pediatric cancer clinical trials.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 814, doi. 10.1002/pst.2039
- By:
- Publication type:
- Article
Comparison of statistical methods for recurrent event analysis using pediatrics asthma data.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 803, doi. 10.1002/pst.2032
- By:
- Publication type:
- Article
Empirical profile Bayesian estimation for extrapolation of historical adult data to pediatric drug development.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 787, doi. 10.1002/pst.2031
- By:
- Publication type:
- Article
Bayesian optimal phase II clinical trial design with time‐to‐event endpoint.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 776, doi. 10.1002/pst.2030
- By:
- Publication type:
- Article
Investigating the appropriateness of different concordance measures in a time‐to‐event setting.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 763, doi. 10.1002/pst.2029
- By:
- Publication type:
- Article
Comparison of two treatments in the presence of competing risks.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 746, doi. 10.1002/pst.2028
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 743, doi. 10.1002/pst.1962
- Publication type:
- Article